Abstract: The present disclosure provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and/or reduce intestinal colonization by Campylobacter.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
December 21, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Inventors:
Lynn A. Joens, Bibiana Law, Alexandra Armstrong
Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.
Abstract: A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.
Abstract: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.
Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.
Type:
Grant
Filed:
November 29, 2019
Date of Patent:
December 7, 2021
Assignee:
QUORUM INNOVATIONS, LLC
Inventors:
Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
Type:
Grant
Filed:
March 3, 2020
Date of Patent:
November 23, 2021
Assignee:
Arexis AB
Inventors:
Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
Abstract: Methods and compositions are provided for lyophilization of bacteria or Listeria strains, such as Listeria monocytogenes. Provided are methods for producing a lyophilized composition comprising a bacteria or Listeria strain, formulations for lyophilization comprising a bacteria or Listeria strain, lyophilized bacteria or Listeria strains, and methods of preparing frozen bacteria or Listeria strains for lyophilization.
Type:
Grant
Filed:
August 29, 2018
Date of Patent:
November 23, 2021
Assignee:
Advaxis, Inc.
Inventors:
David Fela, Anu Wallecha, Mike Grace, Melissa Gosse
Abstract: The present invention describes vaccine compositions for treatment and/or prevention against sea lice infestation in salmon. The present invention further describes nucleic acids, host cells, vectors and methods of using said vaccine for the prevention and/or treatment of sea lice infestation in salmon.
Type:
Grant
Filed:
August 16, 2017
Date of Patent:
November 9, 2021
Assignee:
Pharmaq AS
Inventors:
Jose de Jesus de la Fuente Garcia, Marinela Contreras Rojo, Margarita Maria Villar Rayo, Marius Andre De Feijter Karlsen, Bjorn Erik Brudeseth, Karine Lindmo Yttredal, Christer Ross Wiik-Nielsen, Rolf Hetlelid Olsen, Liv Blom Hungerholdt
Abstract: Compositions and methods are described that provide controlled release of stabilized bacteria into the oral cavity on consumption of a food, candy, gum, or similar substance so as to promote colonization of oral surface by the bacteria. Bacteria are selected to treat an oral condition, such as oral disease, halitosis, and/or stained enamel on consumption of the food.
Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, 5 that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.
Type:
Grant
Filed:
April 4, 2018
Date of Patent:
October 12, 2021
Assignee:
THE UAB RESEARCH FOUNDATION
Inventors:
Charitharth Vivek Lal, Namasivayam Ambalavanan, Amit Gaggar, Casey Morrow
Abstract: Methods are used for obtaining, cataloguing, and/or storing data derived from a biological source using a flow cell body, electrodes, and an imaging assembly. The data may include DNA and/or RNA obtained from a biological source, such as from the cells of an organism. The methods may be used to obtain, catalog, and/or store data such as DNA or RNA sequence from a pathogen such as a virus and/or a bacteria, human health data over time, and immune system information from an individual. The data obtained using the disclosed methods may be used for a variety of different purposes, including the manufacture of vaccine compositions, and for restoring the immune system of an individual who has undergone an immune system depleting event. The methods may be used for storage of biological cells, which may be used for the screening of compounds, such as small molecules with potential for therapeutic indications.
Type:
Grant
Filed:
May 26, 2020
Date of Patent:
October 5, 2021
Assignee:
ILLUMINA, INC.
Inventors:
Tarun Khurana, Ali Agah, Aathavan Karunakaran, Xi-Jun Chen
Abstract: The present invention provides for a fusion protein comprising (1) a bacterial microcompartment (BMC) shell protein comprising one or more subunit, and (2) a first component of a specific-binding pair, operably linked to the BMC shell protein such that the first component faces (i) a lumen (inside) side, or (ii) outside of a BMC shell formed incorporating the fusion protein and the fusion protein does not disrupt or prevent the folding of the BMC shell protein or the ability of the BMC shell protein to integrate with other BMC shell proteins into a BMC shell; wherein the first component is capable of forming a stable or irreversible interaction with a second component of the specific-binding pair.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
September 28, 2021
Assignees:
The Regents of the University of California, Board of Trustees of Michigan State University
Inventors:
Andrew R. Hagen, Cheryl A. Kerfeld, Nancy B. Sloan, Markus Sutter, Bryan H. Ferlez
Abstract: In order to provide a transformant by which a high containment effect is obtained and which can be prepared by a simple procedure, a method for producing the transformant, and a method for detecting the presence of a reduced phosphorous compound with use of the transformant, a transformant in accordance with an embodiment of the present invention is a transformant which is defective in functions of a gene encoding a phosphate transporter protein and a gene encoding a phosphate ester transporter protein and into which a gene encoding a hypophosphite transporter protein is introduced.
Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
September 28, 2021
Assignee:
NORTHWESTERN UNIVERSITY
Inventors:
Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
Abstract: Methods and kits for the detection of toxic cyanobacteria in a sample by analyzing the sample for the presence antibodies raised in a host, where the presence of antibodies is indicative of toxic cyanobacteria, are described.
Type:
Grant
Filed:
June 27, 2019
Date of Patent:
September 21, 2021
Assignee:
The University of Toledo
Inventors:
David Kennedy, Steven Haller, R. Mark Wooten, Deepa Mukundan, Apurva Lad, John Presloid, Jason Huntley, Bruce Levison
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
November 4, 2019
Date of Patent:
September 21, 2021
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.
Type:
Grant
Filed:
December 4, 2018
Date of Patent:
September 14, 2021
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.